Friday, 4 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 13, 2026

CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP

View original at seekingalpha.com
CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP Earnings Call Insights: CareTrust REIT (CTRE) Q4 2025 MANAGEMENT VIEW * David Sedgwick, CEO, described 2025 as a “transformational year” for CareTrust, highlighting a record pace of investments and the company’s expansion into the U.K…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2025 was a transformational year for CareTrust with record pace of investments and expansion into U.K. care home market and U.S. SHOP

    80% confidence
  • Data analytics team is prioritized on building out SHOP capabilities but will ultimately impact the whole organization

    80% confidence
  • The difference for continued strong growth is that the team is deeper and more capable, and they have the U.K. and SHOP TAMs to play in as well

    80% confidence
  • The $500 million pipeline is about half U.K. care homes, about one-third U.S. skilled nursing, and the rest is a combination of SHOP deal, triple-net seniors and a couple of small loans

    80% confidence
  • The skilled nursing environment is in a really good place right now with labor in a much better place than recent history

    80% confidence
  • Most competition is seen in SHOP where cap rates continue to compress as investors seek more exposure

    80% confidence
  • With great operators and beefy coverage, CareTrust can manage through any headwinds in skilled nursing

    80% confidence
  • 2026 guidance does not assume any new investments, dispositions, debt repayments, or equity issuances beyond those announced to date

    80% confidence
  • CareTrust doubled its team of professionals in 2025 and brought in-house capabilities like tax and data science

    80% confidence
  • Q4 normalized FFO increased 42.7% year-over-year to $104.1 million and normalized FAD increased 38.7% to $103 million

    80% confidence
  • Investment pipeline remains strong at approximately $500 million

    80% confidence
  • SHOP deals are heavily marketed and the company targets a low double-digit IRR

    80% confidence
  • Q4 investments totaled approximately $562 million with a blended stabilized yield of 8.8%

    80% confidence
  • The start of 2026 feels very much like deja vu all over again compared to the beginning of 2025

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com
CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP — Source | Via News | ViaNews EU